Unlike existing MS therapies that primarily manage inflammatory relapses, Immunic's experimental drug has a dual mechanism. It both curbs inflammation and directly protects neurons from cell death, addressing the underlying disability progression that current treatments largely fail to stop.

To build investor confidence in the high-risk neuroscience field, Neurocrine employs a dual strategy. It highlights its own proven track record while simultaneously de-risking its pipeline by targeting biological pathways already validated by competitors, aiming to create superior, best-in-class medicines rather than pursuing unproven science.

Historical failures in CNS drugs stem from treating severe, late-stage pathology. Success will come from using better biomarkers to intervene earlier and combining therapies. The speaker envisions a future of 'rational polypharmacy,' where drugs targeting different pathological drivers (e.g., excitability, inflammation) are used in concert.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

The next wave of neuroscience therapeutics is shifting from managing broad symptoms (e.g., in autism) to precision therapies. By identifying genetic underpinnings of a disease, developers can create drugs that target the specific biology of patient subpopulations, aiming for disease modification rather than just symptomatic relief.

French startup Elk Edonia is developing a first-in-class depression therapy targeting the intracellular transcription factor Elk One. Unlike traditional antidepressants acting on extracellular synapses, this small molecule modulates gene expression related to neuroplasticity and inflammation, aiming to make depression an acute, treatable condition rather than a chronic one.

Derek Small posits that GLP-1s succeed in metabolic disease by modulating a "network phenomenon," not a single target. He applies this thesis to neuroscience, focusing on synaptic function and neuroinflammation as the core network that can create systemic brain resilience, similar to how GLP-1s impact metabolic health.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

Instead of targeting complex downstream glutamate receptors, Leal Therapeutics inhibits a single upstream enzyme, glutaminase. This mechanistically simpler approach avoids the off-target effects of receptor-based drugs and allows for direct, quantifiable measurement of target engagement, a major advantage in CNS trials.